Laursen T, Lemming L, Jørgensen J O, Klausen I C, Christiansen J S
Medical Department M (Endocrinology), Aarhus University Hospital, Kommunehospitalet and Centre for Clinical Pharmacology, Aarhus University, Denmark.
Horm Res. 1998;50(5):284-91. doi: 10.1159/000023292.
Lipoprotein (a) (Lp(a)) is a risk marker for the development of atherosclerotic coronary heart disease. Growth hormone (GH) administration to GH-deficient (GHD) adults increases serum Lp(a) concentrations, and the levels of Lp(a) and GH are correlated in patients with acromegaly. Studies in rats have demonstrated differential effects of constant and intermittent GH patterns on levels of certain lipoproteins. The aim of the present studies was to describe the impact of intermittent and continuous patterns of GH delivery to GHD patients on serum levels of Lp(a) and other lipoproteins.
In one study (A) 10 GHD patients received in random order a fixed GH dose intravenously as: (1) continuous infusion; (2) eight bolus injections, and (3) a combination of 1 and 2. Each study lasted 36 h and was preceded by at least 4 weeks without GH. In another study (B) 13 GHD patients received GH in random order as: (1) continuous subcutaneous (s.c.) infusion, and (2) daily s.c. injections in the evening for 1 month each. The patients were studied during steady-state conditions at the end of each treatment period.
In study A Lp(a) levels increased significantly following continuous (p < 0.05) and combined patterns (p < 0.02) of GH administration to GH-deprived GHD patients, whereas the increase after GH bolus injections alone was not significant (p = 0.14). In study B significantly higher (p < 0.05) serum levels of Lp(a) were obtained after continuous s.c. infusion as compared with daily s.c. injections of GH. Concentrations of the high-density lipoprotein (HDL) cholesterol were significantly lower (p < 0.02) after the continuous GH pattern. Similarly, the HDL fraction Apo A-1 tended to be lower with constant GH delivery (p = 0. 052). Serum levels of total cholesterol, triglyceride and Apo B were similar on the two occasions.
Short-term GH administration to GH-deprived GHD patients increased serum Lp(a), but only significantly with continuous delivery. During more prolonged GH exposure, constant s.c. infusion of GH resulted in slightly raised Lp(a) levels and reduced HDL and Apo A1 levels as compared with intermittently administered GH. The findings are consistent with the more effective induction of serum IGF-I levels after continuous patterns of GH delivery previously reported in GHD patients. Longer-term data are needed before conclusions with respect to the impact of the pattern of GH administration on, e.g., the risk of developing coronary heart disease can be drawn.
脂蛋白(a)[Lp(a)]是动脉粥样硬化性冠心病发生的一个风险标志物。对生长激素缺乏(GHD)的成年人给予生长激素(GH)会使血清Lp(a)浓度升高,并且在肢端肥大症患者中Lp(a)水平与GH水平相关。对大鼠的研究表明,持续和间歇性GH模式对某些脂蛋白水平有不同影响。本研究的目的是描述向GHD患者间歇性和持续性给予GH对血清Lp(a)水平及其他脂蛋白的影响。
在一项研究(A)中,10例GHD患者按随机顺序静脉给予固定剂量的GH,方式如下:(1)持续输注;(2)8次推注;(3)1和2的联合方式。每项研究持续36小时,且在此之前至少4周未使用GH。在另一项研究(B)中,13例GHD患者按随机顺序接受GH,方式如下:(1)持续皮下(s.c.)输注;(2)每晚皮下注射,各持续1个月。在每个治疗期结束时的稳态条件下对患者进行研究。
在研究A中,向GH缺乏的GHD患者持续给予GH(p<0.05)及联合方式给予GH(p<0.02)后,Lp(a)水平显著升高,而单独GH推注后升高不显著(p=0.14)。在研究B中,与每日皮下注射GH相比,持续皮下输注后血清Lp(a)水平显著更高(p<0.05)。持续GH模式后高密度脂蛋白(HDL)胆固醇浓度显著更低(p<0.02)。同样,持续给予GH时HDL组分Apo A-1也有降低趋势(p=0.052)。两次检测时总胆固醇、甘油三酯和Apo B的血清水平相似。
对GH缺乏的GHD患者短期给予GH可使血清Lp(a)升高,但仅持续给药时升高显著。在更长时间的GH暴露期间,与间歇性给予GH相比,持续皮下输注GH导致Lp(a)水平略有升高,HDL和Apo A1水平降低。这些发现与先前报道的GHD患者持续给予GH模式后更有效地诱导血清IGF-I水平一致。在得出关于GH给药模式对例如冠心病发生风险的影响的结论之前,需要更长时间的数据。